A Phase 3 interventional study of Daratumumab and Lenalidomide in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Completed at 146 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-01.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.
Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 9th largest by enrollment, is one of 4 that started in 2014, is one of 24 in phase 3, and was the 3rd registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Eden Biltibo · Sites in United States
Ages 18–70
AbbVie · Sites in United States, Australia, Belgium and 9 more countries
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
By country, each count listing its studies:
daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 84 · Phase 3 25 · Phase 4 4
First in 2008; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 569 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 132 interventional studies. Of the 55 that completed or were terminated, 28 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 132 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
126 studies in Multiple Myeloma by Johnson & Johnson: 13 open now, 33 under way, 12 of them phase 3. Of 82 finished, 33 (40%) have results posted.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 13th largest by enrollment of the 100 interventional ones that give a count, is one of 7 that started in 2014, is one of 35 in phase 3, and was the 53rd registered.
Johnson & Johnson’s Multiple Myeloma studies by the year they started, since 1995.
19 of the studies testing daratumumab in Multiple Myeloma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06952478Phase 3CelltrionA Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma | 2027-03-08 |
| NCT04009109Alliance Foundation Trials, LLC.Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | 2026-12 |
| NCT06697483Peking University People's HospitalRisk Stratification and MRD-driven Maintenance for MM After ASCT | 2026-12-31 |
| NCT04991103University of Alabama at BirminghamMinimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) | 2027-01-01 |
| NCT03829371University of Turin, ItalySTUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | 2027-01-03 |
Add all 19 to your calendar (.ics) → With an account.
Among the 132 studies testing daratumumab in Multiple Myeloma, from their registry updates:
Among Johnson & Johnson’s 126 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple myeloma.
This is a randomized (participants will be assigned by chance to study treatments), open-label (all participants and study personnel will know the identity of the study treatments), active-controlled (none of the study treatments are placebo), parallel-group (both treatment arms will run at the same time), multicenter study. In this study, daratumumab, lenalidomide, and low-dose dexamethasone (DRd) will be compared with lenalidomide and low dose dexamethasone (Rd) in participants with relapsed or refractory multiple myeloma. Participants will be randomized in a 1:1 ratio to receive either DRd or Rd. The study will include a Screening Phase, a Treatment Phase (involving treatment cycles of approximately 28 days in length), and a Follow-up Phase. The Treatment Phase will extend from the administration of the first dose of study medication until disease progression or unacceptable toxicity. Participants will also discontinue study treatment if: they become pregnant; have their dose held for more than 28 days (or if 3 consecutive planned doses of daratumumab are missed for reasons other than toxicity); or for safety reasons (for example, adverse event). The Follow-up Phase will begin at the end of treatment and will continue until death, loss to follow-up, consent withdrawal for study participation, or the final overall survival (OS) analysis, whichever occurs first. Eligible participants from Rd group who have had sponsor confirmed disease progression will be offered the option for treatment with daratumumab monotherapy (of 28 days cycle). The primary endpoint will be progression-free survival (PFS). Analysis of the primary endpoint was performed at a pre-specified point determined by PFS events with a clinical cutoff of March 7, 2016 when 169 events of death or progression had occurred. The end of study is anticipated at approximately 6 years after the last participant is randomized. Blood and urine samples will be obtained at time points during the study, together with bone marrow aspirates/biopsies and skeletal surveys. Participant safety will be assessed throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During each 28-day treatment cycle, participants will receive daratumumab, lenalidomide, and dexamethasone.
Drug: Daratumumab · Drug: Lenalidomide · Drug: Dexamethasone
During each 28-day treatment cycle, participants will receive lenalidomide and dexamethasone.
Drug: Lenalidomide · Drug: Dexamethasone
Daratumumab 16mg/kg will be administered as an intravenous (IV) infusion (into the vein) as per the following schedule: once a week during treatment cycles 1 and 2; every 2 weeks during treatment cycles 3 to 6; and every 4 weeks for cycles 7 and onwards. Following amendment 8, participants receiving daratumumab IV have the option to switch to daratumumab subcutaneous (SC) 1800 mg/dose until documented progression, unacceptable toxicity, or the end of study on Day 1 of any cycle, at the discretion of the investigator.
Lenalidomide will be administered at a dose of 25 mg orally (by mouth) on Days 1 through 21 of each treatment cycle.
Dexamethasone (or equivalent in accordance with local standards) will be administered as a total dose of 40 mg weekly (or 20 mg weekly for participants \> 75 years old or with a body mass index \< 18.5).
Progression-free Survival (PFS)
PFS: duration from date of randomization to either progressive disease (PD)/death, whichever occurred first. PD: defined as meeting any 1 of following criteria: Increase of greater than equal to (\>=)25 percent(%) in level of serum M-protein from lowest response value and absolute increase must be \>=0.5 gram per deciliter (g/dL); Increase of \>=25% in 24-hours(h) urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be \>=200 mg/24h; Only in participants without measurable serum and urine M-protein levels: increase of \>=25% in difference between involved and uninvolved free light chain (FLC) levels from lowest response value and absolute increase must be \>10 mg/dL; Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) attributed solely to plasma cell (PC) proliferative disorder.
Time frame: From randomization to either disease progression or death whichever occurs first (up to 21 months)
Time to Disease Progression (TTP)
TTP was defined as time from date of randomization to date of first documented evidence of progressive disease (PD). PD was defined as meeting any one of following criteria: Increase of \>=25% in level of serum M-protein from lowest response value and absolute increase must be \>=0.5 g/dL; Increase of \>=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be \>=200 mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of \>=25% in difference between involved and uninvolved free light chain (FLC) levels from lowest response value and absolute increase must be \>10 milligram per deciliter (mg/dL); Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to plasma cell (PC) proliferative disorder.
Time frame: From randomization to disease progression (up to 21 months)
Percentage of Participants Who Achieved Very Good Partial Response (VGPR) or Better
VGPR or better is defined as the percentage of participants who achieved VGPR, complete response (CR) and stringent complete response (sCR) according to the International Myeloma Working Group criteria (IMWG). IMWG criteria for VGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis, or \>=90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of \>90% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. In addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required; CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% PCs in bone marrow; sCR: CR and normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4 color flow cytometry.
Time frame: From randomization to disease progression (up to 21 months)
Percentage of Participants With Negative Minimal Residual Disease (MRD)
Minimal residual disease was assessed for all participants who achieved a complete response (CR) or stringent complete response (sCR). CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% PCs in bone marrow; sCR: CR and normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4 color flow cytometry. The MRD negativity rate was defined as the percentage of participants who had negative MRD assessment at any time point after the first dose of study drugs by evaluation of bone marrow aspirates or whole blood at 10\^ minus (-) 4, 10\^-5, 10\^-6 threshold.
Time frame: From randomization to the date of first documented evidence of PD (up to 87.5 months)
Overall Response Rate
Overall response rate was defined as the percentage of participants who achieved a partial response (PR) or better according to the International Myeloma Working Group (IMWG) criteria, during or after study treatment. IMWG criteria for PR: \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria, in addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required.
Time frame: From randomization to disease progression (up to 21 months)
Overall Survival (OS)
Overall survival was measured from the date of randomization to the date of the participant's death.
Time frame: From randomization to date of death due to any cause (up to 87.5 months)
Time to Response
Time to response was defined as the time between the date of randomization and the first efficacy evaluation that the participant met all criteria for partial response (PR) or better.
Time frame: From randomization up to first documented CR or PR (up to 21 months)
Duration of Response (DOR)
DOR was defined for participants with confirmed response (PR or better) as time between first documentation of response and disease progression/death due to PD, whichever occurs first. PD was defined as meeting any one of following criteria: Increase of \>=25% in level of serum M-protein from lowest response value and absolute increase must be \>=0.5g/dL; Increase of \>=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be \>=200mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of \>=25% in difference between involved and uninvolved FLC levels from lowest response value and absolute increase must be \>10mg/dL; Definite increase in size of existing bone lesions/soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5mg/dL) that can be attributed solely to PC proliferative disorder.
Time frame: From randomization to the date of first documented evidence of PD (up to 21 months)
Time to Subsequent Anticancer Treatment
Time to subsequent anticancer treatment was defined as the time from randomization to the start of subsequent anticancer treatment or death due to progressive disease (PD), whichever occurs first.
Time frame: From randomization to date of start of subsequent anticancer treatment or death due to PD, whichever occured first (up to 87.5 months)
| Milestone | Lenalidomide, Low-dose Dexamethasone (Rd) | Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) |
|---|---|---|
| Started | 283 | 286 |
| Treated (safety population) | 281 | 283 |
| Completed | 0 | 0 |
| Not completed | 283 | 286 |
| Withdrew: Death | 172 | 153 |
| Withdrew: Withdrawal by subject | 16 | 12 |
| Withdrew: Lost to follow-up | 4 | 2 |
| Withdrew: Progressive disease | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: End of data collection | 90 | 118 |
PFS: duration from date of randomization to either progressive disease (PD)/death, whichever occurred first. PD: defined as meeting any 1 of following criteria: Increase of greater than equal to (\>=)25 percent(%) in level of serum M-protein from lowest response value and absolute increase must be \>=0.5 gram per deciliter (g/dL); Increase of \>=25% in 24-hours(h) urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be \>=200 mg/24h; Only in participants without measurable serum and urine M-protein levels: increase of \>=25% in difference between involved and uninvolved free light chain (FLC) levels from lowest response value and absolute increase must be \>10 mg/dL; Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) attributed solely to plasma cell (PC) proliferative disorder.
| months | Lenalidomide, Low-dose Dexamethasone (Rd) | Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) |
|---|---|---|
| Progression-free Survival (PFS) | 18.43 (13.86 to NA) | NA (NA to NA) |
TTP was defined as time from date of randomization to date of first documented evidence of progressive disease (PD). PD was defined as meeting any one of following criteria: Increase of \>=25% in level of serum M-protein from lowest response value and absolute increase must be \>=0.5 g/dL; Increase of \>=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be \>=200 mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of \>=25% in difference between involved and uninvolved free light chain (FLC) levels from lowest response value and absolute increase must be \>10 milligram per deciliter (mg/dL); Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to plasma cell (PC) proliferative disorder.
| months | Lenalidomide, Low-dose Dexamethasone (Rd) | Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) |
|---|---|---|
| Time to Disease Progression (TTP) | 18.43 (14.78 to NA) | NA (NA to NA) |
VGPR or better is defined as the percentage of participants who achieved VGPR, complete response (CR) and stringent complete response (sCR) according to the International Myeloma Working Group criteria (IMWG). IMWG criteria for VGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis, or \>=90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of \>90% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. In addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required; CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% PCs in bone marrow; sCR: CR and normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4 color flow cytometry.
| percentage of participants | Lenalidomide, Low-dose Dexamethasone (Rd) | Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) |
|---|---|---|
| Percentage of Participants Who Achieved Very Good Partial Response (VGPR) or Better | 44.2 (38.3 to 50.3) | 75.8 (70.4 to 80.7) |
Minimal residual disease was assessed for all participants who achieved a complete response (CR) or stringent complete response (sCR). CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% PCs in bone marrow; sCR: CR and normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4 color flow cytometry. The MRD negativity rate was defined as the percentage of participants who had negative MRD assessment at any time point after the first dose of study drugs by evaluation of bone marrow aspirates or whole blood at 10\^ minus (-) 4, 10\^-5, 10\^-6 threshold.
| percentage of participants | Lenalidomide, Low-dose Dexamethasone (Rd) | Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) |
|---|---|---|
| MRD negative rate (10^-4) | 10.2 (7.0 to 14.4) | 40.6 (34.8 to 46.5) |
| MRD negative rate (10^-5) | 6.7 (4.1 to 10.3) | 33.2 (27.8 to 39.0) |
| MRD negative rate (10^-6) | 1.8 (0.6 to 4.1) | 13.3 (9.6 to 17.8) |
Overall response rate was defined as the percentage of participants who achieved a partial response (PR) or better according to the International Myeloma Working Group (IMWG) criteria, during or after study treatment. IMWG criteria for PR: \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria, in addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required.
| percentage of participants | Lenalidomide, Low-dose Dexamethasone (Rd) | Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) |
|---|---|---|
| Overall Response Rate | 76.4 | 92.9 |
Overall survival was measured from the date of randomization to the date of the participant's death.
| months | Lenalidomide, Low-dose Dexamethasone (Rd) | Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) |
|---|---|---|
| Overall Survival (OS) | 51.84 (43.99 to 60.02) | 67.58 (53.13 to 80.53) |
Time to response was defined as the time between the date of randomization and the first efficacy evaluation that the participant met all criteria for partial response (PR) or better.
| months | Lenalidomide, Low-dose Dexamethasone (Rd) | Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) |
|---|---|---|
| Time to Response | 1.3 (1.1 to 1.9) | 1.0 (1.0 to 1.1) |
DOR was defined for participants with confirmed response (PR or better) as time between first documentation of response and disease progression/death due to PD, whichever occurs first. PD was defined as meeting any one of following criteria: Increase of \>=25% in level of serum M-protein from lowest response value and absolute increase must be \>=0.5g/dL; Increase of \>=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be \>=200mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of \>=25% in difference between involved and uninvolved FLC levels from lowest response value and absolute increase must be \>10mg/dL; Definite increase in size of existing bone lesions/soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5mg/dL) that can be attributed solely to PC proliferative disorder.
| months | Lenalidomide, Low-dose Dexamethasone (Rd) | Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) |
|---|---|---|
| Duration of Response (DOR) | 17.4 (17.4 to NA) | NA (NA to NA) |
Time to subsequent anticancer treatment was defined as the time from randomization to the start of subsequent anticancer treatment or death due to progressive disease (PD), whichever occurs first.
| months | Lenalidomide, Low-dose Dexamethasone (Rd) | Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) |
|---|---|---|
| Time to Subsequent Anticancer Treatment | 23.1 (18.6 to 26.3) | 69.3 (49.7 to 82.8) |
Collected over From randomization up to 30 days after last dose of study treatment (up to 87.5 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenalidomide, Low-dose Dexamethasone (Rd) | — | 148/281 (52.7%) | 268/281 (95.4%) |
| Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | — | 205/283 (72.4%) | 278/283 (98.2%) |
| Event | Lenalidomide, Low-dose Dexamethasone (Rd) | Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) |
|---|---|---|
| PneumoniaInfections and infestations | 32/281 | 48/283 |
| Lower respiratory tract infectionInfections and infestations | 3/281 | 14/283 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/281 | 13/283 |
| PyrexiaGeneral disorders | 5/281 | 13/283 |
| InfluenzaInfections and infestations | 7/281 | 12/283 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 10/281 | 12/283 |
| Acute kidney injuryRenal and urinary disorders | 11/281 | 8/283 |
| BronchitisInfections and infestations | 7/281 | 10/283 |
| SepsisInfections and infestations | 8/281 | 7/283 |
| DiarrhoeaGastrointestinal disorders | 6/281 | 8/283 |
| Event | Lenalidomide, Low-dose Dexamethasone (Rd) | Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 136/281 | 185/283 |
| DiarrhoeaGastrointestinal disorders | 105/281 | 169/283 |
| Upper respiratory tract infectionInfections and infestations | 74/281 | 123/283 |
| FatigueGeneral disorders | 87/281 | 119/283 |
| AnaemiaBlood and lymphatic system disorders | 117/281 | 118/283 |
| CoughRespiratory, thoracic and mediastinal disorders | 43/281 | 107/283 |
| NasopharyngitisInfections and infestations | 62/281 | 100/283 |
| ConstipationGastrointestinal disorders | 77/281 | 94/283 |
| ThrombocytopeniaBlood and lymphatic system disorders | 90/281 | 92/283 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 61/281 | 87/283 |
| Age, Continuous(years) | Lenalidomide, Low-dose Dexamethasone (Rd) | Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | Total |
|---|---|---|---|
| Mean | 64.3 ± 8.84 | 64.4 ± 9.03 | 64.4 ± 8.93 |
| Sex: Female, Male(Participants) | Lenalidomide, Low-dose Dexamethasone (Rd) | Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | Total |
|---|---|---|---|
| Female | 119 | 113 | 232 |
| Male | 164 | 173 | 337 |
| Region of Enrollment(Participants) | Lenalidomide, Low-dose Dexamethasone (Rd) | Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | Total |
|---|---|---|---|
| Australia | 9 | 9 | 18 |
| Belgium | 10 | 12 | 22 |
| Canada | 17 | 17 | 34 |
| Denmark | 7 | 10 | 17 |
| France | 36 | 21 | 57 |
| Germany | 7 | 11 | 18 |
| Greece | 8 | 11 | 19 |
| Israel | 20 | 19 | 39 |
| Japan | 15 | 21 | 36 |
| Korea, Republic of | 20 | 20 | 40 |
| Netherlands | 3 | 1 | 4 |
| Poland | 13 | 15 | 28 |
| Russian Federation | 30 | 18 | 48 |
| Spain | 25 | 26 | 51 |
| Sweden | 15 | 16 | 31 |
| Taiwan, Province of China | 9 | 11 | 20 |
| United Kingdom | 24 | 27 | 51 |
| United States | 15 | 21 | 36 |
| Stage of Disease (ISS)(Participants) | Lenalidomide, Low-dose Dexamethasone (Rd) | Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | Total |
|---|---|---|---|
| I | 140 | 137 | 277 |
| II | 86 | 93 | 179 |
| III | 57 | 56 | 113 |
| No. of Prior Lines of Therapy(Participants) | Lenalidomide, Low-dose Dexamethasone (Rd) | Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | Total |
|---|---|---|---|
| 1 | 146 | 149 | 295 |
| 2 | 80 | 85 | 165 |
| 3 | 38 | 38 | 76 |
| >3 | 19 | 14 | 33 |
Showing the first 100 of 146 sites across 18 countries. Choose a country and city above to see the rest.
Ran from Jul 2014 to primary completion in Mar 2016, 19 months.
Results were first posted in Feb 2017, 11 months after primary completion.
Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 19 months is below that.
Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daratumumab
Janssen Research & Development, LLC →